Loading
Exact Sciences Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 13 Nov 2024.
Exact Sciences Corp: what insiders have been doing
Every trade that managers of Exact Sciences Corp disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Madison, United States. It was founded in 1995. In the past year (18 October 2025 to 18 October 2026), 46 filings came from 14 insiders.
No insider bought on the market over the period, while 4 insiders filed 5 sales totalling €1.3M. At €671k, the sale published on 27 October 2025 by Zanotti Katherine S is the largest of the period.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 7 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
For context, the typical company on the same exchange (median of 5,816 companies) published 19 filings over the same period, against 46 filings here. Since 2016, the database holds 2 purchases and 48 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 3.25 bn USD and net income at -207.9 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
286
Thresholds
n/a
Buy Volume
€943,158
2 ops. · all time
Sell Volume
€14M
48 ops. · all time
Who traded when
BuySaleJames Herriott3 sales
James Edward Doyle2 sales
Brian Baranick1 sale
Jacob A. Orville1 sale
Katherine S. Zanotti1 sale
Kevin T. Conroy1 buy
Analyst consensus: bullish or bearish?
Analysts rate Exact Sciences Corp Hold (neutral), based on 10 analysts. Average price target: US$106.30.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,475 of 24,148 companies
33.4
score / 100
Value27
Quality40
FCF yld·
Earn yld-0.9%
EV/EBITDA·
ROE-8.7%
Gross mgn70%
Net mgn-6.4%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$104.91
Analyst consensus
10 analystsHold
US$105.00Target US$106.30(+1%)US$118.00
Income statement
RevenueUS$2.8B
Gross profitUS$1.9B70% margin
Net income-US$179M-6.4% margin
Valuation
PER (forward)55.2x
P/Book8.3x
Beta1.44
Balance sheet & cash
Market capUS$20B
Debt / Equity106%
Profitability & ownership
ROE-8.7%
ROA-1.6%
% insiders1.2%
% institutions86.5%
Last declaration on 23 March 2026
Declarations286 total
33,321 shares0Common StockSEC:0001193125-26-118765:0
53,323 shares0Common StockSEC:0001193125-26-118754:0
89,911 shares0Common StockSEC:0001193125-26-118759:0
60,389 shares0Common StockSEC:0001193125-26-118758:0
119,312 shares0Common StockSEC:0001193125-26-118755:0
3,244 sharesCommon StockSEC:0001193125-26-118740:0
68,195 sharesCommon StockSEC:0001193125-26-118762:0
52,164 sharesCommon StockSEC:0001193125-26-118752:0
16,406 sharesCommon StockSEC:0001193125-26-118748:0
55,361 sharesCommon StockSEC:0001193125-26-118747:0
6,725 sharesCommon StockSEC:0001193125-26-118745:0
52,564 sharesCommon StockSEC:0001193125-26-118744:0
20,640 sharesCommon StockSEC:0001193125-26-118743:0
7,738 sharesCommon StockSEC:0001193125-26-118742:0
3,900 shares@ US$5.030.8% of flowCommon StockSEC:0001193125-26-089302:0
18,143 shares0Common StockSEC:0001193125-26-089303:0
13,181 shares0Common StockSEC:0001193125-26-082828:0
3,955 shares0Common StockSEC:0001193125-25-337156:0
1,648 shares0Common StockSEC:0001193125-25-337152:0
2,009 shares@ US$101.822.2% of flowCommon StockSEC:0001193125-25-337155:1
4,799 shares@ US$101.825.3% of flowCommon StockSEC:0001193125-25-337155:3
7,539 shares@ US$101.828.3% of flowCommon StockSEC:0001193125-25-337155:5
14,614 shares@ US$101.8216.1% of flowCommon StockSEC:0001193125-25-337155:7
8,151 shares@ US$101.829.0% of flowCommon StockSEC:0001193125-25-337155:9
21,594 shares@ US$101.8223.8% of flowCommon StockSEC:0001193125-25-337155:11
25 of 286 declarations
About Exact Sciences Corp
Exact Sciences Corp. is a U.S.-based company listed on the Nasdaq (EXAS) in the United States. Headquartered in Madison, Wisconsin, the company focuses on cancer screening, early detection, and precision oncology diagnostics. Founded in 1995, Exact Sciences has evolved from a niche molecular diagnostics player into one of the better-known names in oncology testing, building its franchise around non-invasive screening, clinical validation, and physician decision support.
The company’s business is organized around two main pillars: Screening and Precision Oncology. In Screening, Exact Sciences is best known for Cologuard, its at-home colorectal cancer screening test, which has become the company’s flagship product and a key driver of brand recognition. More recently, the company launched Cancerguard, a multi-cancer early detection blood test available in the United States as a laboratory-developed test. In Precision Oncology, Exact Sciences markets Oncotype DX, a genomic test designed to help clinicians assess recurrence risk and guide treatment decisions in certain breast cancer settings. The portfolio is supported by ongoing clinical studies, biomarker development, and a broader innovation pipeline aimed at improving cancer detection and treatment guidance.
Read moreShow less
From a competitive standpoint, Exact Sciences holds a meaningful position in the fast-growing cancer diagnostics market. Its competitive advantages include strong clinical evidence, established physician awareness, reimbursement relationships, and a recognized consumer-facing brand in colorectal screening. At the same time, the business operates in a highly competitive and regulated environment, where adoption depends on clinical utility, payer coverage, and continued evidence generation. The company’s geographic footprint remains primarily centered in the United States, although management has pointed to longer-term international opportunities.
Recent developments are especially important for investors. In February 2026, Exact Sciences reported record full-year 2025 results, with revenue growth and improved cash generation. In September 2025, it launched Cancerguard in the U.S., adding a new platform in multi-cancer early detection. In November 2025, Exact Sciences announced a definitive merger agreement with Abbott Laboratories, a major strategic event that could materially change the company’s ownership structure and future operating profile. Overall, Exact Sciences looks like an innovative U.S. healthcare diagnostics company with strong exposure to the structural growth of cancer screening and precision medicine.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
